Press Releases 3 Investor Relations Press Releases Events Presentations Press Releases Year None20232022202120202019201820172016 Sep 21, 2023 DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4) Sep 19, 2023 DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT) Sep 11, 2023 DermTech Appoints Mark Aguillard as Chief Commercial Officer Aug 25, 2023 DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 DermTech Reports Second-Quarter 2023 Financial Results Jul 19, 2023 DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jul 17, 2023 DermTech Announces Release Date for Second-Quarter 2023 Financial Results Jul 12, 2023 DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jun 28, 2023 DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations Jun 14, 2023 ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT) Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 33 Investor Tools Print Email Page Email Alerts RSS Feeds Contact IR
Press Releases Year None20232022202120202019201820172016 Sep 21, 2023 DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4) Sep 19, 2023 DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT) Sep 11, 2023 DermTech Appoints Mark Aguillard as Chief Commercial Officer Aug 25, 2023 DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2023 DermTech Reports Second-Quarter 2023 Financial Results Jul 19, 2023 DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jul 17, 2023 DermTech Announces Release Date for Second-Quarter 2023 Financial Results Jul 12, 2023 DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) Jun 28, 2023 DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations Jun 14, 2023 ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT) Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 33
Sep 21, 2023 DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
Sep 19, 2023 DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jul 19, 2023 DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jul 12, 2023 DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jun 28, 2023 DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
Jun 14, 2023 ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)
